Previous 10 | Next 10 |
Q4 2022 consolidated revenue growth of 14.2% to $21.4 million FY2022 revenue totaled $80.1 million or growth of ~15%, in line with guidance FY2023 operating plan to focus on achieving positive Adjusted EBITDA 1 by year end based on commercial business growth and tighter budget...
Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form bas...
Presentation at Conference on Retroviruses and Opportunistic Infections (CROI) demonstrates association between excess visceral abdominal fat (EVAF) reduction and decreased prevalence of metabolic syndrome with tesamorelin treatment Data provide further evidence of potential utility of te...
MONTREAL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the pl...
MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its four...
FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash flow from operating activities FY2023 operat...
Poster for presentation at the 34 th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in healthy and tumor tissues Extensive dataset underscores potential of SORT1 as a new anticanc...
Theratechnologies Inc. (THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 A.M. ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Chief Financial Officer Christi...
Theratechnologies press release ( NASDAQ: THTX ): Q3 Revenue of $20.81M (+16.6% Y/Y) beats by $0.07M . Given the increase in revenue and the smaller increase in expenses in the Q3 2022, net loss improved to $7.55M from $9.51M in the Q3 2021. North American Revenue ...
- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19% - TH1902 Phase 1 basket trial proceeding as planned - On track to meet FY2022 Revenue Guidance $79 - $82 million MONTREAL, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...